articleTop 1% cited
What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?
Medical Care · 2008 · Vol. 46(4) · pp. 349–356
R. Scott Braithwaite✉(Yale University)David Meltzer(University of Chicago)Joseph T. King(VA Connecticut Healthcare System)Douglas Leslie(Yale University)Mark S. Roberts(University of Pittsburgh)
Abstract
It is very unlikely that $50,000 per QALY is consistent with societal preferences in the United States.
Health Systems, Economic Evaluations, Quality of LifeHealthcare cost, quality, practicesEconomic and Environmental ValuationQuality-adjusted life yearDecision ruleActuarial scienceMedicineValue of lifeHealth careQuality of life (healthcare)Cost effectivenessCost–benefit analysisDemography
MeSH terms
AdultCost-Benefit AnalysisDecision Support TechniquesFemaleHealth PolicyHumansInsurance, HealthLife ExpectancyMaleMiddle AgedReference ValuesTime FactorsUnited StatesHealth Care RationingAge Distribution
Citations
585
FWCI
126.45
field-weighted impact
References
34
Percentile
100%
vs. same field & year
Citations per year
Cited by
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
The Lancet Oncology · 2008 · 5,801 citations
Related articles
What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?
Medical Care · 2008 · 585 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.